These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31781972)

  • 21. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J
    Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in pediatric pulmonary arterial hypertension.
    Ivy D
    Curr Opin Cardiol; 2012 Mar; 27(2):70-81. PubMed ID: 22274573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.
    Rosenzweig EB; Abman SH; Adatia I; Beghetti M; Bonnet D; Haworth S; Ivy DD; Berger RMF
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30545978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on pediatric pulmonary arterial hypertension.
    Ivy D; Frank BS
    Curr Opin Cardiol; 2021 Jan; 36(1):67-79. PubMed ID: 33136663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].
    Kaemmerer H; Gorenflo M; Hoeper M; Huscher D; Ewert P; Pittrow D
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1247-52. PubMed ID: 23720182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New paradigm for pulmonary arterial hypertension treatment.
    Tamura Y; Channick RN
    Curr Opin Pulm Med; 2016 Sep; 22(5):429-33. PubMed ID: 27434819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary arterial hypertension in children: a medical update.
    Rosenzweig EB; Barst RJ
    Indian J Pediatr; 2009 Jan; 76(1):77-81. PubMed ID: 19391006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk stratification and medical therapy of pulmonary arterial hypertension.
    Galiè N; Channick RN; Frantz RP; Grünig E; Jing ZC; Moiseeva O; Preston IR; Pulido T; Safdar Z; Tamura Y; McLaughlin VV
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30545971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical therapies for pulmonary arterial hypertension.
    Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
    Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary arterial hypertension: a current review of pharmacological management.
    Sahni S; Ojrzanowski M; Majewski S; Talwar A
    Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of treatment goals in paediatric pulmonary arterial hypertension.
    Ploegstra MJ; Douwes JM; Roofthooft MT; Zijlstra WM; Hillege HL; Berger RM
    Eur Respir J; 2014 Dec; 44(6):1616-26. PubMed ID: 25034572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of pulmonary hypertension.
    Hoeper MM; McLaughlin VV; Dalaan AM; Satoh T; Galiè N
    Lancet Respir Med; 2016 Apr; 4(4):323-36. PubMed ID: 26975811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.
    Zhang Y; Yu X; Jin Q; Luo Q; Zhao Z; Zhao Q; Yan L; Liu Z
    Heart Fail Rev; 2019 Nov; 24(6):949-965. PubMed ID: 31044326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of pulmonary arterial hypertension].
    Jaïs X; Bonnet D
    Presse Med; 2010 Jun; 39 Suppl 1():1S22-32. PubMed ID: 20732614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel strategies for treatment of pulmonary arterial hypertension.
    Jasińska-Stroschein M; Orszulak-Michalak D
    Postepy Hig Med Dosw (Online); 2017 Jul; 71(0):577-588. PubMed ID: 28791952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Targeted therapy of pulmonary arterial hypertension (PAH)].
    Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostacyclins and pulmonary arterial hypertension in children.
    Wu Y; Liu HM; Gu L; Li QW; Zhu L
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):37-45. PubMed ID: 35049017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
    Channick R; Preston I; Klinger JR
    Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.